Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Shanafelt TD, Wang XV, Hanson CA, Paietta EM, et al. Blood 2022;140:112-120.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shanafelt TD, Wang XV, Hanson CA, Paietta EM, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood 2022;140:112-120.
PMID: 35427411